KR101257909B1 - Pharmaceurtical compositions for the prevention or treatment of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient - Google Patents
Pharmaceurtical compositions for the prevention or treatment of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient Download PDFInfo
- Publication number
- KR101257909B1 KR101257909B1 KR1020110105871A KR20110105871A KR101257909B1 KR 101257909 B1 KR101257909 B1 KR 101257909B1 KR 1020110105871 A KR1020110105871 A KR 1020110105871A KR 20110105871 A KR20110105871 A KR 20110105871A KR 101257909 B1 KR101257909 B1 KR 101257909B1
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- extract
- wild ginseng
- mushroom
- mycelium
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 106
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 95
- 239000004480 active ingredient Substances 0.000 title claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 title abstract description 120
- 201000011510 cancer Diseases 0.000 title abstract description 98
- 239000000203 mixture Substances 0.000 title abstract description 29
- 238000011282 treatment Methods 0.000 title abstract description 15
- 230000002265 prevention Effects 0.000 title abstract description 14
- 240000004371 Panax ginseng Species 0.000 title description 88
- 235000002789 Panax ginseng Nutrition 0.000 title 1
- 241000001727 Tropicoporus linteus Species 0.000 title 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 114
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 94
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 94
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- 241000208340 Araliaceae Species 0.000 claims abstract 7
- 239000000843 powder Substances 0.000 claims description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 18
- 201000005202 lung cancer Diseases 0.000 claims description 18
- 208000020816 lung neoplasm Diseases 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 abstract description 40
- 238000002156 mixing Methods 0.000 abstract description 12
- 235000020710 ginseng extract Nutrition 0.000 abstract description 10
- 229930012538 Paclitaxel Natural products 0.000 abstract description 9
- 229960001592 paclitaxel Drugs 0.000 abstract description 9
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract description 9
- 239000002246 antineoplastic agent Substances 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 8
- 235000013376 functional food Nutrition 0.000 abstract description 6
- 230000006872 improvement Effects 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 description 39
- 238000002360 preparation method Methods 0.000 description 38
- 238000004519 manufacturing process Methods 0.000 description 19
- 238000000605 extraction Methods 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 14
- 241000700159 Rattus Species 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 150000004804 polysaccharides Chemical class 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- -1 cancer vaccines Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 231100000405 induce cancer Toxicity 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000222518 Agaricus Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 244000115658 Dahlia pinnata Species 0.000 description 1
- 235000012040 Dahlia pinnata Nutrition 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000222684 Grifola Species 0.000 description 1
- 241000123222 Hericium Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000123107 Phellinus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000222355 Trametes versicolor Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003684 cardiac depression Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- YXJHJCDOUFKMBG-BMZHGHOISA-M riboflavin sodium Chemical compound [Na+].OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)[N-]C2=O YXJHJCDOUFKMBG-BMZHGHOISA-M 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 상황버섯 균사체와 산삼 배양근 혼합 추출물을 유효성분으로 함유하는 암 예방 및 개선용 건강기능 식품 조성물에 관한 것으로, 본 발명에 따른 상황버섯 균사체와 산삼 배양근 혼합 추출물은 상황버섯 균사체와 산삼 배양근을 1:1 내지 5:1의 중량비율로 혼합함으로써 상황버섯 또는 산삼 단독 추출물보다 우수한 항암효과를 나타내며, 특히 상황버섯 균사체와 산삼 배양근을 3:1의 중량비율로 혼합하는 경우에 가장 우수한 항암 효과를 나타내는바, 이는 현재 항암제로 널리 사용되는 탁솔의 항암 효과보다도 우수하므로 본 발명에 따른 상황버섯 균사체와 산삼 배양근 혼합 추출물은 암의 예방 또는 개선을 위한 건강기능 식품 조성물로 유용하게 사용될 수 있을 뿐만 아니라, 암의 예방 또는 치료를 위한 약학적 조성물로 유용하게 사용될 수 있다.The present invention relates to a health functional food composition for preventing and improving cancer containing the mushroom mushroom mycelium and wild ginseng culture root mixed extract as an active ingredient, the mushroom extract mycelium and wild ginseng culture root mixed extract according to the present invention comprises the mushroom mushroom mycelium and wild ginseng culture root By mixing at a weight ratio of 1: 1 to 5: 1, the anticancer effect is superior to that of the situation mushroom or wild ginseng extract alone, and the best anticancer effect is especially obtained when the mushroom mushroom mycelium and wild ginseng culture root are mixed at a weight ratio of 3: 1. Since it is superior to the anticancer effect of Taxol, which is currently widely used as an anticancer agent, the situation mushroom mycelium and wild ginseng cultured root extract according to the present invention can be usefully used as a health functional food composition for the prevention or improvement of cancer, It can be usefully used as a pharmaceutical composition for the prevention or treatment of cancer The.
Description
본 발명은 상황버섯 균사체와 산삼 배양근 혼합 추출물을 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물에 관한 것이다.
The present invention relates to a pharmaceutical composition for preventing or treating cancer containing the mushroom extract mycelium and wild ginseng cultured root extract as an active ingredient.
암이란 일반적으로 인체조직을 이루고 있는 세포의 세포주기에 이상이 생겨 정상적으로 분화하지 않고, 성장을 조절할 수 없이 커진 것 중 악성종양을 말한다. 암은 개시(initiation), 촉진(promotion) 및 진행(progression)의 세 단계를 거쳐 발생하며, 충분한 양의 발암물질만으로 발생될 수 있으나 실제적으로는 환경이나 음식물 속에 포함된 소량의 발암개시물질(initiator)에 의해 세포 돌연변이(개시세포)가 일어나고 이렇게 세포들의 수가 기하급수적으로 늘면서 발암촉진물질(tumor promotor)의 자극에 의해 비정상적인 세포분열이 일어났을 때 비로소 암 조직이 형성되기 시작한다고 알려져 있다.
Cancer generally refers to a malignant tumor that has grown abnormally in the cell cycle of the cells constituting the human tissue and has not been normally differentiated and is unable to control growth. Cancer occurs through three stages: initiation, promotion, and progression, and can occur with a sufficient amount of carcinogens, but in reality a small amount of carcinogens in the environment or food It is known that cancer tissues begin to form when abnormal cell division occurs due to the stimulation of a tumor promotor as cell mutations (starting cells) occur exponentially and the number of cells increases exponentially.
환경 악화와 노년인구의 증가로 세계 암 발생률이 매년 5% 이상 증가하고 있으며, 1997년 암을 원인으로 한 사망자가 600만 명으로 질병 사망률의 12%에 달했다. 국내에서도 매년 10만 명의 암환자가 새롭게 발생하고 5만 여명이 매년 사망하고 있으며, 암환자 증가율도 10%에 이르고 있다. 1999년 국립암센터의 통계에 따르면 환자는 12만 명으로서 남자는 위암(24%), 간암(16%), 폐암(16%), 대장암(10%)의 순서로, 여자는 위암(16%), 자궁경부암(12%), 유방암(15%), 대장암(10%)의 순서로 암 환자가 발생했다.
The world's cancer incidence is increasing by more than 5% every year due to deterioration of the environment and the increase of elderly population.In 1997, 6 million people died of cancer, accounting for 12% of the mortality rate. In Korea, 100,000 new cancer patients occur every year, about 50,000 die each year, and cancer patients increase by 10%. According to the National Cancer Center's statistics in 1999, there were 120,000 patients, men in stomach cancer (24%), liver cancer (16%), lung cancer (16%), colon cancer (10%), and women in stomach cancer (16). %), Cervical cancer (12%), breast cancer (15%) and colorectal cancer (10%).
이러한 암의 치료를 위해서 외과적 치료, 화학요법, 생물요법, 방사선요법 등이 이용되고 있다. 화학요법은 흔히 말하는 약물요법으로서 핵산 알킬화제, 대사 길항제, 천연물, 호르몬제 등의 합성된 화학물질을 이용한 것이며, 생물요법은 우리 몸이 원래 가지고 있는 면역 기능을 회복시키거나 증진시켜 암세포의 활동력을 약화시킴으로써 암의 진행을 막는 것으로서, 사이토카인, 면역요법제, 유전자 치료제, 암 백신, 신생혈관형성 억제제 등이 있다. 현재까지 이러한 방법들을 단독 혹은 병용하여 치료에 응용하고 있으나 부작용, 약제내성, 재발 등으로 완벽한 치료법이 없는 상태이다.Surgical treatment, chemotherapy, biotherapy, radiotherapy and the like are used for the treatment of such cancer. Chemotherapy is a commonly used drug therapy that uses synthetic chemicals such as nucleic acid alkylating agents, metabolic antagonists, natural products, and hormones. Biotherapy reduces the activity of cancer cells by restoring or enhancing the immune function of our body. By preventing cancer progression, there are cytokines, immunotherapeutics, gene therapy agents, cancer vaccines, angiogenesis inhibitors, and the like. Until now, these methods have been applied to treatment alone or in combination, but there are no complete treatments due to side effects, drug resistance, and recurrence.
지금까지 항암제 연구는 암세포처럼 세포분열이 왕성한 조직에 대한 세포증식 억제를 근거로 하여 행하여지기 때문에 세포분열이 빠른 피부, 점막, 골수 같은 정상조직 세포에도 독성을 나타나게 된다. 따라서 효과적인 항암제 개발을 위해서는 암세포에만 특이적으로 작용하고 정상세포에 대해 세포 독성이 적은 항암 활성물질의 탐색이 이루어져야 한다.
Until now, anticancer drug research has been conducted on the basis of suppression of cell proliferation in active cell division such as cancer cells, so that the cell division is toxic to normal tissue cells such as skin, mucous membranes and bone marrow. Therefore, in order to develop an effective anticancer agent, it is necessary to search for an anticancer active substance that acts specifically on cancer cells and is less cytotoxic to normal cells.
이에 많은 발명자들이 항암활성을 가지는 천연 소재를 찾아오고 있으며 그 중에서도 버섯류의 항암 활성에 대한 많은 연구결과들이 보고되고 있다. 현재까지 항암 활성이 있는 버섯류로는 영지(Ganoderma lucidum), 상황버섯, 아가리쿠스(신령버섯), 동충하초(vegetable worms), 천마(Gastrodia elata), 구름버섯(Coriolus versicolor), 복령(Poria cocos), 장수버섯(아까시재목버섯 Fomitella fraxinea), 잎새버섯( Grifola frondosa), 노루궁뎅이(Hericium erinaceum) 및 흰목이(Fremella fuciformis) 등이 알려져 있다.
Many inventors have been searching for natural materials having anticancer activity, and among them, many studies on the anticancer activity of mushrooms have been reported. To date, mushrooms with anticancer activity include Ganoderma lucidum ), situation mushroom, agaricus, vegetable worms, Gastrodia elata), versicolor (Coriolus versicolor), Poria cocos (Poria cocos ), long- lived mushrooms fraxinea ), leaf mushroom ( Grifola) frondosa ), Hericium beetle erinaceum ) and Fremella fuciformis .
상기 버섯 천연물 중에서 상황버섯(Phellinus linteus)은 목질진흙버섯이라고도 하며, 동의보감에서는 상목이(桑木耳)라는 이름으로 탕액편에 기록되어 있다. 갓은 지름 6 내지 12 ㎝, 두께 2 내지 10 ㎝로, 반원 모양, 편평한 모양, 둥근 산 모양, 말굽 모양 등 여러 가지 모양을 하고 있다. 표면에는 어두운 갈색의 털이 짧고 촘촘하게 나있다가 자라면서 없어지고 각피화한다. 검은빛을 띤 갈색의 고리 홈이 나 있으며 가로와 세로로 등이 갈라진다. 가장자리는 선명한 노란색이고 아랫면은 황갈색이며 살도 황갈색이다. 자루가 없고 포자는 연한 황갈색으로 공 모양이다. 다년생으로 뽕나무 등에 겹쳐서 나는 목재부후균이며, 초기에는 진흙 덩어리가 뭉쳐진 것처럼 보이다가 다 자란 후에는 나무 그루터기에 혓바닥을 내민 모습이어서 수설(樹舌)이라고도 한다. 상황버섯이 함유하고 있는 다당체가 면역체계를 활성화시켜 항암 활성 및 면역활성, 항종양 효과를 나타내는 것으로 널리 알려져 있어 지금까지 우리나라를 비롯하여 일본과 중국 등에서 많은 연구가 진행되어 있고, 연구결과에서 상황버섯의 다당체 성분이 항암 및 면역 증강에 효과가 있는 것으로 나타났으며, 귀중한 약재로서 한국에서는 대량으로 재배하고 있다. 약용하기 위해 달이면 노란색이거나 연한 노란색으로 맑게 나타나며, 맛과 향이 없는 것이 특징이다. 맛이 순하고 담백하여 먹기에도 좋으며, 한국, 일본, 오스트레일리아, 북아메리카 등에 자생한다.
Phellinus mushrooms among the natural mushrooms linteus ) is also known as woody mud mushroom, and it is written on the liquid juice piece under the name Sangmokyi (桑 木耳) in Dongbogam. The shade is 6 to 12 cm in diameter and 2 to 10 cm in thickness, and has various shapes such as semicircle shape, flat shape, round mountain shape, and horseshoe shape. Dark brown hairs on the surface are short and dense, then disappear and become cuticles. There is a blackish brown ring groove and the back is split horizontally and vertically. Edge is bright yellow, bottom is yellowish brown, and flesh is yellowish brown. No sack, spores pale yellowish brown. It is a perennial tree that grows on mulberry trees, and is a woody fungus.It seems to be a collection of mud in the early days. Polysaccharides contained in situation mushrooms are widely known to have anti-cancer activity, immune activity and anti-tumor effect by activating the immune system. So far, many studies have been conducted in Korea, Japan and China. The polysaccharide component has been shown to be effective in anticancer and immune enhancement, and it is cultivated in large quantities in Korea as a valuable medicine. For medicinal use, the moon appears clear as yellow or light yellow and has no taste and aroma. It is mild in taste and light to eat, and is native to Korea, Japan, Australia, and North America.
한편, 산삼은 예로부터 신비한 영약으로 취급되어 전설 속에나 등장할 만큼 희귀식물로서, 희귀성 및 약효의 신비성으로 인해 전설적인 약용식물로 알려져 있다. 산이 거칠고 골짜기가 깊은 곳에서 자생하는 산삼은 가장 귀하고 가치가 있는 약초로 특히, 천연 산삼의 경우 발견율이 더욱 희박해지고 있어 소수의 심마니들에 의해서 발견되는 신비의 영약으로 알려져 있다. 산삼의 형태적 특징은 첫째, 뇌두의 길이는 재배된 삼에 비하여 현저히 길며 보통 6 내지 9 ㎝ 이상 되는 것도 있다. 둘째, 뿌리는 재배삼과 같이 미황색이 아닌 약간 거무스레한 흰색에 가깝고 동체의 상단 부분 또는 지근까지 가락지 테의 모양이 굴곡지어 있고 세근 곳곳에는 좁쌀알과 같은 것이 부착되어 있는데 이를 옥주라 한다. 셋째, 산삼은 오래 묵은 삼일수록 뇌두가 길며 긴 뇌두의 곳곳에서 새로이 형성된 뿌리가 비대 생장하여 달리아처럼 집합근을 형성하기도 하지만 재배삼에 비하여 중량이 적다. 넷째, 재배삼의 뿌리의 길이가 30 ㎝ 내외인 것에 비해 산삼은 뿌리의 길이가 길며 1 m 이상씩 긴 것도 있다. 산삼의 지상부 형태 중 특이한 점은 자연 풍토나 환경에 순응하면서 생장하기 때문에 10년 이상 되어도 장엽이 3개 정도로 적은 것도 있다. 그리고 잎의 이면은 은색을 띄며, 소엽병과 엽병이 굵고 화경이 짧은 것이 특징이다.On the other hand, wild ginseng has been treated as a mysterious elixir from ancient times, and is a rare plant that appears in the legend. Wild ginseng, which grows wild in deep valleys and deep valleys, is the most precious and valuable herb. Especially, natural wild ginseng is becoming rarer and is known as a mysterious medicine found by a few simnies. Morphological characteristics of wild ginseng First, the length of the brain head is significantly longer than the cultivated ginseng, usually 6 to 9 cm or more. Second, the root is close to slightly dark white rather than yellowish like cultivated ginseng, and the shape of the rim is curved up to the upper part or root of the fuselage. Third, wild ginseng has longer brain heads, and newly formed roots grow in large parts of the long brain head, forming aggregate roots like dahlias, but having less weight than cultivated ginseng. Fourth, the length of the root of cultivated ginseng is about 30 ㎝, while the length of the wild ginseng is longer than 1 m. The peculiarity of wild ginseng is that it grows while adapting to the natural climate and environment, so there are few long leaves after 10 years. And the back side of the leaves is silver, characterized by thick leaflets and leaflets, and short flower scenes.
일반적으로 인삼의 효능을 보면, 혈행 개선, 조혈작용, 심장 강하, 노화 방지, 혈압 정상화, 저하된 간기능 정상화, 위장병 치료, 당뇨병 치료, 암의 예방 및 치유 증진, 항피로, 스트레스 해소, 알레르기성 체질 개선, 냉증 치료, 갱년기 장애 해소, 류머티즘 치료, 정력 강화, 두뇌 활동 촉진, 시력 개선, 피부미용 및 모발 개선, 알콜 중독 해독 및 면역 기능 강화 등의 약효가 알려져 있다.In general, the benefits of ginseng include improved blood circulation, hematopoiesis, cardiac depression, anti-aging, normalized blood pressure, normalized decreased liver function, gastrointestinal disease, diabetes treatment, cancer prevention and healing, anti-fatigue, stress relief, allergy It is known to improve the constitution, treat cold symptoms, relieve menopausal disorders, treat rheumatism, strengthen energy, promote brain activity, improve eyesight, improve skin care and hair, detoxify alcohol and strengthen immune function.
산삼의 적응증이나 효용은 인삼과 비슷하나 약 효과가 월등하다. 산삼에는 배당체 (glycosides) 성분인 사포닌(saponin)을 비롯하여, 질소함유 화합물로서 단백질, 아미노산, 핵산 및 알칼로이드, 지용성분으로 지방산, 정유, 폴리아세틸렌, 페놀화합물, 파이토스테롤 및 테르페노이드, 당류로서 단당류, 올리고당, 다당류 및 펙틴질 그리고 비타민류와 무기질 등 매우 다양한 성분들이 함유되어 있다.
The indications and benefits of wild ginseng are similar to ginseng, but the drug is superior. Wild ginseng contains saponins, glycosides, proteins, amino acids, nucleic acids and alkaloids as nitrogen-containing compounds, fatty acids, essential oils, polyacetylene, phenolic compounds, phytosterols and terpenoids, and sugars as fat-soluble components. It contains a wide variety of ingredients, including oligosaccharides, polysaccharides and pectins, vitamins and minerals.
현재까지는 항암효과가 뛰어난 상황버섯과 산삼을 단독으로 이용한 의약품이나 기능성 식품들이 다양하게 개발되어 왔다. 특히 대한민국등록특허 제10-0197446호에는 상황버섯 균사체로부터 분리한 분자량 9,000 내지 16,000 또는 153,000 달톤의 항암 면역활성 다당류 및 그 제조방법, 대한민국등록특허 제10-0607907호에는 암의 간전이억제와 면역조절효과를 갖는 상황버섯 추출물을 함유하는 약학적 조성물, 대한민국등록특허 제10-0456089호에는 항암 활성을 갖는 산삼 추출정제액을 정제하는 방법 및 이를 함유하는 조성물과 같이 상황버섯 추출물과 산삼 추출물을 단독으로 제조하는 방법이나 조성물이 공지되어 있을 뿐, 상황버섯과 산삼 추출물을 배합하는 제조방법, 배합제품 또는 이들 배합비율에 따른 항암활성을 포함한 생리활성 증진효과 등에 대한 것은 잘 알려져 있지 않은 실정이다.
Until now, various kinds of medicines and functional foods using the situation mushroom and wild ginseng which have excellent anticancer effects have been developed. Particularly, Korean Patent No. 10-0197446 discloses anticancer immunoactive polysaccharides having a molecular weight of 9,000 to 16,000 or 153,000 Daltons isolated from a situation mushroom mycelium, and a method for preparing the same. Korean Patent No. 10-0607907 discloses liver hepatic metastasis suppression and immunomodulation. Pharmaceutical composition containing a situation mushroom extract having an effect, Korean Patent No. 10-0456089 is a method for purifying wild ginseng extract tablets having anti-cancer activity and the composition containing the same as a situation mushroom extract and wild ginseng extract The manufacturing method and composition are well known, and the manufacturing method of mixing the situation mushroom and wild ginseng extract, the compounded product or the physiological activity enhancing effect including anticancer activity according to these blending ratios are not well known.
이에 본 발명자들은 항암 효과가 우수한 암 예방제 또는 암 개선제를 개발하기 위하여 연구하던 중, 상황버섯 균사체와 산삼 배양근이 1:1 내지 5:1의 중량비율로 혼합된 혼합물의 추출물이 상황버섯 또는 산삼 단독 추출물보다 우수한 항암효과를 나타내어 이를 유효성분으로 함유하는 조성물을 암의 예방 또는 개선을 위한 건강기능 식품 조성물로 유용하게 사용될 수 있을 뿐만 아니라, 암의 예방 또는 치료를 위한 약학적 조성물로 유용하게 사용될 수 있음을 밝힘으로써 본 발명을 완성하였다.
Therefore, the present inventors while studying to develop a cancer preventive agent or cancer improver excellent anti-cancer effect, the extract of the mixture of the situation mushroom mycelium and wild ginseng culture root in a weight ratio of 1: 1 to 5: 1 is the situation mushroom or wild ginseng alone It can be usefully used as a health food composition for the prevention or improvement of cancer, as well as a composition containing it as an active ingredient, showing an excellent anticancer effect than the extract, as well as a pharmaceutical composition for the prevention or treatment of cancer The present invention has been completed by revealing that there is.
본 발명의 목적은 상황버섯 균사체와 산삼 배양근 혼합 추출물을 유효성분으로 함유하는 암 예방 또는 개선용 건강기능 식품 조성물을 제공하는 데 있다.An object of the present invention to provide a health functional food composition for preventing or improving cancer containing a mushroom extract mycelium and wild ginseng culture root mixed extract as an active ingredient.
본 발명의 다른 목적은 상황버섯 균사체와 산삼 배양근 혼합 추출물을 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물을 제공하는 데 있다.
It is another object of the present invention to provide a pharmaceutical composition for preventing or treating cancer, which comprises a mixed mushroom mycelium and wild ginseng cultured root extract as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 상황버섯 균사체와 산삼 배양근의 1:1 내지 5:1 중량비율 혼합 추출물을 유효성분으로 함유하는 암 예방 또는 개선용 건강기능 식품 조성물을 제공한다.In order to achieve the above object, the present invention provides a dietary supplement for cancer prevention or improvement containing 1: 1 to 5: 1 weight ratio mixed extract of the situation mushroom mycelium and wild ginseng culture root as an active ingredient.
또한, 본 발명은 상황버섯 균사체와 산삼 배양근의 1:1 내지 5:1 중량비율 혼합 추출물을 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물을 제공한다.
In another aspect, the present invention provides a pharmaceutical composition for preventing or treating cancer containing 1: 1 to 5: 1 weight ratio mixed extract of the situation mushroom mycelium and wild ginseng culture root as an active ingredient.
본 발명에 따른 상황버섯 균사체와 산삼 배양근 혼합 추출물은 상황버섯 균사체와 산삼 배양근을 1:1 내지 5:1의 중량비율로 혼합함으로써 상황버섯 또는 산삼 단독 추출물보다 우수한 항암효과를 나타내며, 특히 상황버섯 균사체와 산삼 배양근을 3:1의 중량비율로 혼합하는 경우에 가장 우수한 항암 효과를 나타내는바, 이는 현재 항암제로 널리 사용되는 탁솔의 항암 효과보다도 우수하므로 본 발명에 따른 상황버섯 균사체와 산삼 배양근 혼합 추출물은 암의 예방 또는 개선을 위한 건강기능 식품 조성물로 유용하게 사용될 수 있을 뿐만 아니라, 암의 예방 또는 치료를 위한 약학적 조성물로 유용하게 사용될 수 있다.
The situation mushroom mycelium and wild ginseng cultured root extract according to the present invention shows a superior anticancer effect than the situation mushroom or wild ginseng extract by mixing the situation mushroom mycelium and wild ginseng culture root in a weight ratio of 1: 1 to 5: 1, especially the situation mushroom mycelium The best anticancer effect when mixed with wild ginseng culture root at a weight ratio of 3: 1, which is superior to the anticancer effect of Taxol, which is currently widely used as an anticancer agent, is a mixed mushroom mycelium and wild ginseng root culture extract according to the present invention. Not only can be usefully used as a nutraceutical composition for the prevention or improvement of cancer, it can also be usefully used as a pharmaceutical composition for the prevention or treatment of cancer.
도 1은 폐암 세포를 마우스에 이식한 후 14일 동안 본 발명에 따른 제조예 1 내지 3의 추출물을 투여한 경우의 암 부피 억제율을 나타낸 그래프이고;
도 2는 폐암 세포를 마우스에 이식한 후 14일 동안 본 발명에 따른 제조예 1 내지 3의 추출물을 투여한 경우의 암 무게 억제율을 나타낸 그래프이고;
도 3은 폐암 세포를 마우스에 이식한 후 14일 동안 본 발명에 따른 제조예 1 내지 3의 추출물을 투여한 경우의 종양을 나타낸 이미지이고;
도 4는 폐암 세포를 마우스에 이식한 후 14일 동안 본 발명에 따른 제조예 2의 추출물을 다양한 농도로 투여한 경우의 암 부피 억제율을 나타낸 그래프이고;
도 5는 폐암 세포를 마우스에 이식한 후 14일 동안 본 발명에 따른 제조예 2의 추출물을 다양한 농도로 투여한 경우의 암 무게 억제율을 나타낸 그래프이고;
도 6은 폐암 세포를 마우스에 이식한 후 14일 동안 본 발명에 따른 제조예 2의 추출물을 다양한 농도로 투여한 경우의 종양을 나타낸 이미지이다.1 is a graph showing the cancer volume inhibition rate when the extract of Preparation Examples 1 to 3 according to the present invention was administered for 14 days after transplanting lung cancer cells into mice;
2 is a graph showing the cancer weight inhibition rate when the extract of Preparation Examples 1 to 3 according to the present invention was administered for 14 days after transplanting lung cancer cells into mice;
3 is an image showing a tumor when the extract of Preparation Examples 1 to 3 according to the present invention is administered for 14 days after transplanting lung cancer cells into a mouse;
4 is a graph showing cancer volume inhibition rate when the extract of Preparation Example 2 according to the present invention was administered at various concentrations for 14 days after transplanting lung cancer cells into mice;
5 is a graph showing cancer weight inhibition rate when the extract of Preparation Example 2 according to the present invention was administered at various concentrations for 14 days after transplanting lung cancer cells into mice;
FIG. 6 is an image showing tumors when the extract of Preparation Example 2 according to the present invention was administered at various concentrations for 14 days after transplanting lung cancer cells into mice.
본 발명은 상황버섯 균사체와 산삼 배양근 혼합 추출물을 유효성분으로 함유하는 암 예방 또는 개선용 건강기능 식품 조성물을 제공한다.
The present invention provides a health functional food composition for preventing or improving cancer containing the mushroom extract mycelium and wild ginseng cultured root extract as an active ingredient.
이하, 본 발명을 상세히 설명한다.
Hereinafter, the present invention will be described in detail.
본 발명에 따른 상황버섯 균사체 추출물은 상황버섯 균사체 또는 이의 건조물로부터 추출하여 얻을 수 있다.
The mushroom mushroom mycelium extract according to the present invention can be obtained by extracting from mushroom mushroom mycelium or a dried product thereof.
본 발명에 따른 산삼 배양근 추출물은 산삼 배양근 또는 이의 건조물로부터 추출하여 얻을 수 있다.
Wild ginseng culture root extract according to the present invention can be obtained by extracting from wild ginseng culture root or its dried product.
본 발명에 따른 상황버섯 균사체와 산삼 배양근 혼합 추출물은 초임계추출, 아임계추출, 고온추출, 고압추출 또는 초음파추출법 등의 추출장치를 이용한 방법 또는 XAD 및 HP-20을 포함한 흡착수지를 이용하는 방법 등 당업계의 통상적인 추출방법을 사용할 수 있으며, 바람직하게는 가온하며 환류 추출 또는 상온에서 추출하여 제조할 수 있으나, 이에 한정되는 것은 아니다. 추출 회수는 1 내지 5회인 것이 바람직하며, 3회 반복 추출하는 것이 더욱 바람직하나, 이에 한정되는 것은 아니다. Situary mushroom mycelium and wild ginseng cultured root extract according to the present invention is a method using an extraction device such as supercritical extraction, subcritical extraction, high temperature extraction, high pressure extraction or ultrasonic extraction method or a method using the adsorption resin including XAD and HP-20 Conventional extraction methods in the art may be used, and may be prepared by heating at reflux extraction or extraction at room temperature, but are not limited thereto. The number of extraction is preferably 1 to 5 times, and more preferably 3 times of extraction, but is not limited thereto.
상기 추출물은 물, 유기용매 또는 이들의 혼합용매를 이용하여 추출될 수 있다. 상기 유기용매는 C1 내지 C4의 알코올, 초산에틸, 염화메틸렌 및 클로로포름으로 이루어지는 군으로부터 선택되는 어느 하나 또는 이들의 혼합용매인 것이 바람직하고, C1 내지 C4의 알코올인 것이 더욱 바람직하고, 에탄올인 것이 더욱 바람직하며, 40 내지 60%의 에탄올로 추출하는 것이 가장 바람직하다. 이때, 상기 추출용매는 상황버섯 균사체와 산삼 배양근 분말의 5 내지 20배의 부피를 사용할 수 있다.
The extract may be extracted using water, an organic solvent or a mixed solvent thereof. The organic solvent is preferably any one or a mixed solvent selected from the group consisting of C 1 to C 4 alcohols, ethyl acetate, methylene chloride and chloroform, more preferably C 1 to C 4 alcohols, More preferred is ethanol, most preferably with 40-60% ethanol. At this time, the extraction solvent may be used 5 to 20 times the volume of the situation mushroom mycelium and wild ginseng culture root powder.
본 발명에 따른 상황버섯 균사체와 산삼 배양근 혼합 추출물은 상황버섯 균사체와 산삼 배양근의 1:1 내지 5:1 중량비율 혼합 추출물인 것이 바람직하며, 3:1 중량비율 혼합 추출물인 것이 더욱 바람직하다.
The mushroom mushroom mycelium and wild ginseng culture root mixed extract according to the present invention is preferably a 1: 1 to 5: 1 weight ratio mixed extract of the mushroom mushroom mycelium and wild ginseng culture root, and more preferably a 3: 1 weight ratio mixed extract.
일례로 본 발명에 따른 상황버섯 균사체와 산삼 배양근 혼합 추출물은 상황버섯 균사체 분말과 산삼 배양근 분말을 일정 중량비율로 혼합한 후, 환류 냉각장치가 부착된 추출용기에 넣고 분말무게의 5 내지 20배의 부피의 추출용매를 넣고 용액을 끓이며 환류 추출한 후, 일정시간 방치한 다음 거름종이 등으로 여과하여 알코올 추출물을 얻을 수 있다. 추출시간은 2 내지 12시간인 것이 바람직하며, 3 내지 5시간인 것이 더욱 바람직하다. 이후에 농축 또는 동결건조 등의 방법을 추가적으로 수행할 수 있다.
For example, the mixed mushroom mushroom mycelium and wild ginseng cultured root extract according to the present invention, after mixing the mushroom mushroom mycelium powder and wild ginseng cultured root powder in a certain weight ratio, put it in an extraction container with a reflux cooling device 5 to 20 times the weight of the powder After adding a volume of extraction solvent, the solution was boiled and refluxed, left for a certain time, and then filtered through a filter paper to obtain an alcohol extract. The extraction time is preferably 2 to 12 hours, more preferably 3 to 5 hours. Thereafter, a method such as concentration or lyophilization may be additionally performed.
또한, 본 발명은 상황버섯 균사체와 산삼 배양근 혼합 추출물을 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물을 제공한다.
In addition, the present invention provides a pharmaceutical composition for preventing or treating cancer, which contains a mushroom extract mycelium and wild ginseng cultured root extract as an active ingredient.
본 발명에 따른 상황버섯 균사체와 산삼 배양근 혼합 추출물의 항암 효과를 하기의 구체적인 실험결과들을 근거로 설명한다.
The anticancer effect of the mixed mushroom mycelium and wild ginseng culture root extract according to the present invention will be described based on the specific experimental results below.
본 발명에 따른 상황버섯 균사체와 산삼 배양근 혼합 추출물은 항암 효과 평가 실험에서 상황버섯 또는 산삼 단독 추출물보다 우수한 항암효과를 나타냄으로써, 단독 추출물로부터는 예상할 수 없는 상승효과를 나타내는 것을 알 수 있다. 특히 상황버섯 균사체와 산삼 배양근을 3:1의 중량비율로 혼합한 경우에는 암 무게 억제율이 약 63%로 측정됨으로써, 약 47%의 암 무게 억제율을 나타내는 상황버섯 및 약 40%의 암 무게 억제율을 나타내는 산삼 단독 추출물에 비해 암 무게 억제율이 약 1.6배 우수한 것을 알 수 있다(실시예 1, 표 1, 도 1, 도 2 및 도 3 참조).
Situary mushroom mycelium and wild ginseng cultured root extract according to the present invention showed an anticancer effect superior to the situation mushroom or wild ginseng alone extract in the anti-cancer effect evaluation experiment, it can be seen that the synergistic effect is not expected from the single extract. In particular, when the mycelium mushroom mycelium and wild ginseng culture root were mixed at a weight ratio of 3: 1, the cancer weight inhibition rate was measured to be about 63%. It can be seen that cancer weight inhibition rate is about 1.6 times superior to wild ginseng extract alone (see Example 1, Table 1, Figure 1, Figure 2 and Figure 3).
또한, 본 발명에 따른 상황버섯 균사체와 산삼 배양근 혼합 추출물은 투여용량에 따른 항암 효과 평가 실험에서 투여용량이 증가할수록 암 무게 억제율 및 암 부피 억제율이 증가함으로써 용량의존적인 항암 효과를 나타내며, 특히 상황버섯 균사체와 산삼 배양근 3:1 중량비율 혼합 추출물을 200 ㎎/㎏의 용량으로 투여하는 경우에 탁솔에 비해 암 무게 억제율이 약 1.5배, 암 부피 억제율이 약 1.7배 우수한 것을 알 수 있다(실시예 2, 표 2, 도 4, 도 5 및 도 6 참조).
In addition, the situation mushroom mycelium and wild ginseng culture root mixed extract according to the present invention shows a dose-dependent anti-cancer effect by increasing the cancer weight inhibition rate and cancer volume inhibition rate as the dose is increased in the anti-cancer effect evaluation experiment according to the dose. When the mixed mycelium and wild ginseng culture root 3: 1 weight ratio mixed extract is administered at a dose of 200 mg / kg, it can be seen that cancer weight inhibition rate is about 1.5 times and cancer volume inhibition rate is about 1.7 times higher than that of Taxol (Example 2 , Table 2, FIGS. 4, 5 and 6).
따라서, 본 발명에 따른 상황버섯 균사체와 산삼 배양근 혼합 추출물은 상황버섯 균사체와 산삼 배양근을 1:1 내지 5:1의 중량비율로 혼합함으로써 상황버섯 또는 산삼 단독 추출물보다 우수한 항암효과를 나타내며, 특히 상황버섯 균사체와 산삼 배양근을 3:1의 중량비율로 혼합하는 경우에 가장 우수한 항암 효과를 나타내는바, 이는 현재 항암제로 널리 사용되는 탁솔의 항암 효과보다도 우수하므로 본 발명에 따른 상황버섯 균사체와 산삼 배양근 혼합 추출물은 암의 예방 또는 개선을 위한 건강기능 식품 조성물로 유용하게 사용될 수 있을 뿐만 아니라, 암의 예방 또는 치료를 위한 약학적 조성물로 유용하게 사용될 수 있다.
Therefore, the mixed mushroom mushroom mycelium and wild ginseng cultured root extract according to the present invention shows a superior anticancer effect than the situation mushroom or wild ginseng extract by mixing the mushroom fungus mycelium and wild ginseng cultured root at a weight ratio of 1: 1 to 5: 1, in particular, The best anticancer effect was obtained when the mushroom mycelium and wild ginseng culture root were mixed at a weight ratio of 3: 1, which is superior to the anticancer effect of Taxol, which is widely used as an anticancer agent. The extract may be usefully used as a nutraceutical composition for preventing or improving cancer, as well as as a pharmaceutical composition for preventing or treating cancer.
본 발명에 따른 상황버섯 균사체와 산삼 배양근 혼합 추출물을 암의 예방 또는 개선을 목적으로 식품, 음료 등의 건강보조 또는 건강기능성 식품에 첨가할 수 있다. 이 경우, 상황버섯 균사체와 산삼 배양근 혼합 추출물을 식품 첨가물로 사용시에 원료에 대하여 0.01 내지 20 중량%, 바람직하게는 0.1 내지 5 중량%의 양으로 첨가할 수 있다. 유효 성분의 혼합양은 사용목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 그러나, 건강 및 위생을 목적으로 하거나 건강 조절을 목적으로 하는 장기간의 섭취의 경우에 상기 양은 상기 범위 이하일 수 있으며, 안정성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다. 상기 상황버섯 균사체와 산삼 배양근 혼합 추출물을 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.Situation mushroom mycelium and wild ginseng cultured root extract according to the present invention can be added to health supplements or functional foods, such as food, beverages for the purpose of preventing or improving cancer. In this case, the situation mushroom mycelium and wild ginseng culture root mixed extract may be added in an amount of 0.01 to 20% by weight, preferably 0.1 to 5% by weight based on the raw materials when used as a food additive. The blending amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment). However, in the case of long-term intake for health and hygiene purposes or health control purposes, the amount may be below the above range, and since there is no problem in terms of stability, the active ingredient may be used in an amount above the above range. The situation mushroom mycelium and wild ginseng culture root mixed extract may be used with other foods or food ingredients, and may be appropriately used according to conventional methods.
상기 식품의 종류에는 특별한 제한이 없다. 상기 추출물을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸컬릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함하는 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of food. Examples of foods to which the extract can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, and drinks. , Alcoholic beverages and vitamin complexes, and includes all of the health food in the conventional sense.
본 발명의 식품 보조 첨가제는 여러 가지 향미제 또는 천연 탄수화물 등을 사용할 수 있다. 상기 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토오스, 수크로오스 등과 같은 디사카라이드 및 덱스트린, 시클로덱스트린과 같은 폴리사카라이드, 자일리톨, 솔비톨, 에르트리톨 등의 당알코올이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명에 따른 조성물 100 중량부당 일반적으로 약 0.01 내지 0.04 중량부, 바람직하게는 0.02 내지 0.03 중량부이다.
The food supplement additive of the present invention may use various flavors or natural carbohydrates. The natural carbohydrates are sugars such as glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, xylitol, sorbitol, and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 parts by weight, preferably 0.02 to 0.03 parts by weight per 100 parts by weight of the composition according to the present invention.
상기 외에 본 발명에 따른 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 중점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명에 따른 조성물은 천연 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있으며, 첨가제의 비율은 크게 중요하진 않지만 본 발명에 따른 조성물 100 중량부당 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.
In addition to the above, the composition according to the present invention contains various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, Alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the compositions according to the invention may contain pulp for the production of natural fruit juices and vegetable beverages. These components can be used independently or in combination, and the proportion of the additive is not critical, but is usually selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition according to the present invention.
본 발명에 따른 상황버섯 균사체와 산삼 배양근 혼합 추출물을 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물은 하기의 다양한 경구 또는 비경구 투여 형태로 제형화할 수 있으나, 이에 한정되는 것은 아니다.The pharmaceutical composition for preventing or treating cancer containing the situation mushroom mycelium and wild ginseng culture root mixed extract according to the present invention as an active ingredient may be formulated in various oral or parenteral dosage forms as follows, but is not limited thereto.
경구 투여용 제형으로는 예를 들면 정제, 환제, 경/연질 캅셀제. 액제. 현탁제, 유화제, 시럽제. 과립제, 엘릭시르제 등이 있는데, 이들 제형은 상기 유효성분 이외에 통상적으로 사용되는 충진제, 증량제, 습윤제, 붕해제, 활택제, 결합제, 계면활성제 등의 희석제 또는 부형제를 1종 이상 사용할 수 있다. 붕해제로는 한천, 전분, 알긴산 또는 이의 나트륨염, 무수인산일수소 칼슘염 등이 사용될 수 있고, 활택제로는 실리카, 탈크, 스테아르산 또는 이의 마그네슘염 또는 칼슘염, 폴리에틸렌 글리콜 등이 사용될 수 있으며, 결합제로는 마그네슘 알루미늄 실리케이트. 전분 페이스트, 젤라틴, 트라가칸스, 메틸셀룰로오스, 나트륨카복시메틸셀룰로오스, 폴리비닐피롤리딘, 저치환도 하이드록시프로필셀룰로오스 등이 사용될 수 있다. 이외에도 락토즈, 덱스트로오스, 수크로오스, 만니톨, 소르비톨, 셀룰로오스. 글리신 등을 희석제로 사용할 수 있으며, 경우에 따라서는 일반적으로 알려진 비등 혼합물, 흡수제, 착색제, 향미제, 감미제 등을 함께 사용할 수 있다.Formulations for oral administration include, for example, tablets, pills, hard / soft capsules. Liquid. Suspensions, emulsifiers, syrups. Granules, elixirs, and the like, these formulations may be used one or more diluents or excipients, such as fillers, extenders, wetting agents, disintegrants, lubricants, binders, surfactants, etc. that are commonly used in addition to the active ingredient. As a disintegrant, agar, starch, alginic acid or its sodium salt, calcium monohydrogen phosphate anhydride, etc. may be used, and as lubricant, silica, talc, stearic acid or its magnesium salt or calcium salt, polyethylene glycol, etc. may be used. As a binder, magnesium aluminum silicate. Starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidine, low-substituted hydroxypropylcellulose, and the like can be used. In addition to lactose, dextrose, sucrose, mannitol, sorbitol, cellulose. Glycine or the like may be used as a diluent, and in some cases, generally known boiling mixtures, absorbents, colorants, flavors, sweeteners, and the like may be used together.
또한 상황버섯 균사체와 산삼 배양근 혼합 추출물을 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물은 비경구 투여할 수 있으며, 비경구 투여는 피하주사제, 정맥주사제, 근육 내 주사제 또는 흉부 내 주사제를 주입하는 방법에 의한다. 이때, 비경구 투여용 제형으로 제제화하기 위하여 상황버섯 균사체와 산삼 배양근 혼합 추출물을 안정제 또는 완충제와 함께 물에서 혼합하여 용액 또는 현탁액으로 제조하고, 이를 앰플 또는 바이알의 단위 투여형으로 제조할 수 있다. In addition, the pharmaceutical composition for the prevention or treatment of cancer containing a mixed mushroom mycelium and wild ginseng cultured root extract as an active ingredient can be administered parenterally, and parenteral administration is a subcutaneous injection, intravenous injection, intramuscular injection or intramuscular injection. It depends on how to do it. In this case, in order to formulate into a parenteral formulation, the situation mushroom mycelium and wild ginseng culture root mixed extract may be mixed with water with a stabilizer or buffer to prepare a solution or suspension, which may be prepared in a unit dosage form of ampoules or vials.
상기 조성물은 멸균되거나 또는 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염, 완충제 등의 보조제 및 기타 치료적으로 유용한 물질을 함유할 수 있으며, 통상적인 방법인 혼합, 과립화 또는 코팅 방법에 다라 제제화할 수 있다. The composition may be sterile or contain preservatives, stabilizers, hydrating or emulsifiers, salts for controlling osmotic pressure, buffers and other auxiliaries and other therapeutically useful materials, which are conventional methods of mixing, granulating or coating methods. It can be formulated accordingly.
본 발명의 상황버섯 균사체와 산삼 배양근 혼합 추출물을 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물을 단위 용량 형태로 제형화하는 경우, 유효성분으로서 상황버섯 균사체와 산삼 배양근 혼합 추출물을 약 0.1 내지 1,500 ㎎의 단위용량으로 함유되는 것이 바람직하다. 투여량은 환자의 체중, 나이 및 질병의 특수한 성질과 심각성과 같은 요인에 따라 의사의 처방에 따른다. 그러나, 성인 치료에 필요한 투여량은 투여의 빈도와 강도에 따라 하루에 약 1 내지 500 ㎎ 범위가 보통이다. 성인에게 근육 내 또는 정맥 내 투여 시 일 회 투여량으로는 분리하여 하루에 보통 약 5 내지 300 ㎎의 전체 투여량이면 충분할 것이나, 일부 환자의 경우 더 높은 일일 투여량이 바람직할 수 있다.
When formulating a pharmaceutical composition for preventing or treating cancer containing the extract of the situation mushroom mycelium and wild ginseng culture root of the present invention as an active ingredient, the extract of the situation mushroom mycelium and wild ginseng culture root as an active ingredient is about 0.1 to It is preferably contained in a unit dose of 1,500 mg. The dosage depends on the physician's prescription depending on factors such as the patient's weight, age and the particular nature and severity of the disease. However, dosages required for adult treatment typically range from about 1 to 500 mg per day, depending on the frequency and intensity of administration. For intramuscular or intravenous administration to adults, a single dose separate from the usual dosage of about 5 to 300 mg per day would be sufficient, although for some patients a higher daily dose may be desirable.
이하, 본 발명을 실시예를 통하여 상세히 설명한다. 단, 하기의 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기의 실시예에 의해 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail through examples. However, the following examples are illustrative of the present invention, and the present invention is not limited by the following examples.
<< 제조예Manufacturing example 1> 상황버섯 균사체와 산삼 1> Situation Mushroom Mycelia and Wild Ginseng 배양근Cultivator 1:1 혼합 추출물의 제조 Preparation of 1: 1 Mixed Extract
상황버섯 균사체 분말과 산삼 배양근 분말을 1:1 중량비율로 혼합한 후, 환류 냉각장치가 부착된 추출용기에 분말 혼합물을 넣고 분말 무게의 10배 무게에 해당하는 50% 에탄올수용액으로 수욕상에서 4시간씩 3회 가열추출한 뒤 여과하여 여액을 감압, 농축하여 50% 에탄올 추출물을 얻었다. 상기 에탄올 추출물을 물에 현탁하고 동결건조하여 상황버섯 균사체와 산삼 배양근 1:1 혼합 추출물을 제조하였다.
Situary mushroom mycelium powder and wild ginseng cultured root powder were mixed in a 1: 1 weight ratio, and then the powder mixture was placed in an extraction container equipped with a reflux condenser, and then 50% ethanol solution corresponding to 10 times the weight of the powder was used for 4 hours in a water bath. Filtration was carried out three times, followed by filtration, and the filtrate was concentrated under reduced pressure and concentrated to obtain 50% ethanol extract. The ethanol extract was suspended in water and lyophilized to prepare a 1: 1 mixed extract of mushroom mushroom mycelium and wild ginseng culture root.
<< 제조예Manufacturing example 2> 상황버섯 균사체와 산삼 2> Situation Mushroom Mycelia and Wild Ginseng 배양근Cultivator 3:1 혼합 추출물의 제조 Preparation of 3: 1 Mixed Extract
상기 실시예 1에서 상황버섯 균사체 분말과 산삼 배양근 분말을 1:1 중량비율 대신에 3:1 중량비율로 혼합하여 사용하는 것을 제외하고는, 상기 실시예 1과 동일한 방법으로 상황버섯 균사체 분말과 산삼 배양근 3:1 혼합 추출물을 제조하였다.
In the same manner as in Example 1, except that the mushroom mushroom mycelium powder and wild ginseng culture root powder were mixed in a 3: 1 weight ratio instead of 1: 1 weight ratio in Example 1, the situation mushroom mycelium powder and wild ginseng Culture root 3: 1 mixed extract was prepared.
<< 제조예Manufacturing example 3> 상황버섯 균사체 분말과 산삼 3> Situation Mushroom Mycelia Powder and Wild Ginseng 배양근Cultivator 5:1 혼합 추출물의 제조 Preparation of 5: 1 Mixed Extract
상기 실시예 1에서 상황버섯 균사체 분말과 산삼 배양근 분말을 1:1 중량비율 대신에 5:1 중량비율로 혼합하여 사용하는 것을 제외하고는, 상기 실시예 1과 동일한 방법으로 상황버섯 균사체 분말과 산삼 배양근 5:1 혼합 추출물을 제조하였다.
In the same manner as in Example 1, except that the mushroom mushroom mycelium powder and wild ginseng culture root powder were mixed in a 5: 1 weight ratio instead of 1: 1 weight ratio in Example 1, the situation mushroom mycelium powder and wild ginseng Culture root 5: 1 mixed extract was prepared.
<< 비교제조예Comparative Production Example 1> 상황버섯 추출물의 제조 1> Preparation of Situary Mushroom Extract
상황버섯 균사체 분말을 환류 냉각장치가 부착된 추출용기에 넣고 분말 무게의 10배 무게에 해당하는 50% 에탄올수용액으로 수욕상에서 4시간씩 3회 가열추출한 뒤 여과하여 여액을 감압, 농축하여 50% 에탄올 추출물을 얻었다. 상기 에탄올 추출물을 물에 현탁하고 동결건조하여 상황버섯 균사체 분말 추출물을 제조하였다.
Situation of mushroom mycelium powder in an extraction vessel equipped with a reflux condenser, heated and extracted three times in a water bath for 4 hours with a 50% ethanol solution corresponding to 10 times the weight of the powder. An extract was obtained. The ethanol extract was suspended in water and lyophilized to prepare a situation mushroom mycelium powder extract.
<< 비교제조예Comparative Production Example 2> 산삼 추출물의 제조 2> Preparation of Wild Ginseng Extract
산삼 배양근 분말을 환류 냉각장치가 부착된 추출용기에 넣고 분말 무게의 10배 무게에 해당하는 50% 에탄올수용액으로 수욕상에서 4시간씩 3회 가열추출한 뒤 여과하여 여액을 감압, 농축하여 50% 에탄올 추출물을 얻었다. 상기 에탄올 추출물을 물에 현탁하고 동결건조하여 산삼 배양근 분말 추출물을 제조하였다.
The wild ginseng culture root powder was placed in an extraction container equipped with a reflux condenser, heated and extracted three times for 4 hours in a water bath with 50% ethanol solution corresponding to 10 times the weight of the powder. Got. The ethanol extract was suspended in water and lyophilized to prepare a ginseng culture root powder extract.
< 실시예 1> 상황버섯 균사체 분말과 산삼 배양근 혼합 추출물의 항암 효과 평가 < Example 1> Anti-cancer effect evaluation of the situation mushroom mycelium powder and wild ginseng cultured root extract
본 발명에 따른 상황버섯 균사체 분말과 산삼 배양근 혼합 추출물의 항암 효과를 측정하기 위하여 하기의 실험을 수행하였다.In order to measure the anticancer effect of the mushroom mushroom mycelium powder and wild ginseng cultured root extract according to the present invention, the following experiment was performed.
먼저, 실험에 사용한 쥐는 중앙실험동물(주)에서 구입한 일본산 흰 쥐 ICR male로서 체중은 20±2 g이었다. 사육온도는 22±2 ℃이었고, 고형사료(삼양사료 Co.)와 물을 충분히 공급하였다. 매 그룹에 사용한 쥐의 수는 10마리이었고, 그 중에서 표준편차가 큰 2마리를 빼고 나머지 8마리의 결과를 데이터로 정리하였다. 추출용 용매는 1급 시약(E.P.)을 사용하였다. 시료는 대한약품주식회사에서 제조한 멸균생리식염수를 사용하였다. 암세포배양에 사용한 RPMI 1640 배지는 WelGENE Inc.에서 제공한 배지를 사용하였고, 트립신-EDTA는 GIBCO사 것을 사용하였다. 세포배양에 필요한 시험관과 배양용 플라스크 그리고 암세포를 얻기 위한 필터는 팔콘사 것을 사용하였다. 암 이식에 사용한 기구들은 120 ℃에서 30분 동안 소독한 기구들을 사용하였으며, 암의 부피는 디지털 캘리퍼(Digital Caliper)를 사용하여 그 부피를 측정하였다. 실험에 사용한 폐암(Lewis Lung Carcinoma, LLC)세포는 한국생명공학연구원에서 분양받아 사용하였다. 폐암세포는 10% FBS를 넣은 RPMI 1640 배지로 37 ℃의 배양기에서 배양하였고, 부착면으로부터 분리할 때는 트립신-EDTA를 사용하였다. 200 ㎖의 배양용 플라스크에 세포가 차면 2마리의 동물에 이식하여 폐암 세포를 키운 후 그것을 사용하여 동물실험을 진행하였다.First, the rats used in the experiment were Japanese white rat ICR males purchased from Central Experimental Animal Co., Ltd., and weighed 20 ± 2 g. The breeding temperature was 22 ± 2 ℃, and the solid feed (Samyang Feed Co.) and water were sufficiently supplied. The number of rats used in each group was 10, and two of them with large standard deviations were subtracted and the remaining eight were summarized as data. As a solvent for extraction, a primary reagent (E.P.) was used. As a sample, sterile physiological saline prepared by Korea Pharmaceutical Co., Ltd. was used. RPMI 1640 medium used for cancer cell culture was used as a medium provided by WelGENE Inc., and trypsin-EDTA was used as GIBCO. Falcon was used as a filter for obtaining test tubes, culture flasks, and cancer cells necessary for cell culture. The instruments used for cancer implantation were used sterilized for 30 minutes at 120 ℃, the volume of the cancer was measured using a digital caliper (Digital Caliper). The lung cancer cells (Lewis Lung Carcinoma, LLC) used in the experiment were distributed by the Korea Research Institute of Bioscience and Biotechnology. Lung cancer cells were cultured in an incubator at 37 ℃ in RPMI 1640 medium containing 10% FBS, trypsin-EDTA was used to separate from the adhesion surface. When cells were filled in a 200 ml culture flask, two animals were transplanted to grow lung cancer cells, and then animal experiments were performed using them.
항암동물실험은 약 15×15×15 ㎣ 크기로 자란 종양을 수술하여 필터를 이용하여 암세포를 다른 세포와 분리하였으며, 여러 번 세척하여 얻은 암세포를 2×105 cell/㎖의 농도로 만들어 실험동물의 겨드랑이에 0.1 ㎖씩 주사하여 암을 유발하였다. 암 이식 후 다음날부터 14일간 상기 제조예 1 내지 3의 추출물을 각각 200 ㎎/㎏의 용량으로 일본산 흰 쥐에게 매일 경구투여하였다. 비교군으로 상기 비교제조예 1 및 2의 추출물을 각각 200 ㎎/㎏의 용량으로 14일 동안 매일 1회 경구투여 하였으며, 대조군에는 아무런 처리를 하지 않았다. 14일 후, 상기 제조예 1 내지 3의 추출물 및 비교제조예 1 내지 2의 추출물의 투여를 중지한 후, 디지털 캘리퍼(Digital Caliper)를 사용하여 결과를 측정하였다. 암의 부피, 암 부피 억제율 및 암 무게 억제율의 계산은 하기 수학식 1 내지 수학식 3에 의해 계산하였다.Anti-cancer animal experiment is about 15 × 15 × 15 ㎣ Cancer cells were isolated from other cells using a filter that had grown to a tumor grown in size, and cancer cells obtained by washing several times were injected at a concentration of 2 × 10 5 cell / ml into the experimental animal's armpits to induce cancer. It was. After the cancer transplantation, the extracts of Preparation Examples 1 to 3 were orally administered to Japanese white rats at a dose of 200 mg / kg each day for 14 days from the next day. As a comparison group, the extracts of Comparative Preparation Examples 1 and 2 were orally administered once daily for 14 days at a dose of 200 mg / kg, and the control group was not treated. After 14 days, the administration of the extract of Preparation Examples 1 to 3 and the extract of Comparative Preparation Examples 1 and 2 were stopped, and the results were measured using a digital caliper. The calculation of cancer volume, cancer volume inhibition rate and cancer weight inhibition rate was calculated by the following equations (1) to (3).
[수학식 1][Equation 1]
암의 부피(Tumor Volume, TV) = Length(㎜)×Width2 Tumor Volume (TV) = Length (mm) × Width 2
[수학식 2]&Quot; (2) "
암 부피 억제율(Inhibition Ratio of Tumor Volume, IRTV) = (A-B)×100/A Inhibition Ratio of Tumor Volume (IRTV) = (A-B) × 100 / A
A : 아무런 처리를 하지 않은 대조군의 암의 부피A: volume of cancer of control group without any treatment
B : 제조예 내지 비교제조예 추출물을 처리한 실험군의 암의 부피B: volume of the cancer of the experimental group treated with the extract of Preparation Example Comparative Example
[수학식 3]&Quot; (3) "
암 무게 억제율(Inhibition Ratio of Tumor Weight, IRTW) = (C-D)×100/CInhibition Ratio of Tumor Weight (IRTW) = (C-D) × 100 / C
C : 아무런 처리를 하지 않은 대조군의 암의 무게C: weight of cancer of control group without any treatment
D : 제조예 내지 비교예 추출물을 처리한 실험군의 암의 무게
D: weight of cancer of the experimental group treated with the extracts of the preparations and comparative examples
그 결과를 하기 표 1 및 도 1 내지 3에 나타내었다. 모든 데이터는 mean±S.D.로 나타냈으며, 분석은 Anova test를 실시하였고, p values는 0.05 이하인 경우 유의성이 있다고 하였다. 보다 상세하게는 본 발명에 따른 제조예 1 내지 3의 추출물을 투여한 경우에 암 부피 억제율을 도 1에 나타내었고, 암 무게 억제율을 도 2에 나타내었으며, 종양 이미지를 도 3에 나타내었다.The results are shown in Table 1 below and FIGS. 1 to 3. All data were expressed as mean ± SD. The analysis was performed by Anova test, and p values were less than 0.05. In more detail, in the case of administering the extract of Preparation Examples 1 to 3 according to the present invention, the cancer volume inhibition rate is shown in FIG. 1, the cancer weight inhibition rate is shown in FIG. 2, and the tumor image is shown in FIG. 3.
상기 표 1 및 도 1 내지 도 3에 나타낸 바와 같이, 상기 제조예 1 내지 3, 비교제조예 1 내지 2의 추출물을 투여한 경우 아무런 처리를 하지 않은 대조군과 비교하여, 모두 종양크기 및 종양무게가 감소하였으며, 암 부피 억제율 및 암 무게 억제율이 증가하는 것을 알 수 있다. 또한, 상기 제조예 1 내지 3의 추출물을 투여한 경우에는 비교제조예 1 내지 비교제조예 2의 추출물을 단독으로 투여한 경우보다 종양크기 및 종양무게가 작은 것을 알 수 있으며, 암 부피 억제율 및 암 무게 억제율이 우수한 것을 알 수 있다. 특히, 상기 제조예 2(3:1 혼합 추출물)의 추출물을 투여한 경우에는 종양 크기가 1266 ㎣, 종양 무게가 1.27 g 감소한 결과, 암 부피 억제율이 55%, 암 무게 억제율이 63%로 측정됨으로써 가장 우수한 함암 효과를 나타내는 혼합비율임을 알 수 있다. As shown in Table 1 and FIGS. 1 to 3, when the extracts of Preparation Examples 1 to 3 and Comparative Preparation Examples 1 and 2 were administered, the tumor size and tumor weight were all compared with the control group which was not treated at all. It can be seen that the cancer volume inhibition rate and cancer weight inhibition rate are increased. In addition, in the case of administering the extract of Preparation Examples 1 to 3 it can be seen that the tumor size and tumor weight is smaller than the case of administering the extract of Comparative Preparation Examples 1 to 2 alone, cancer volume inhibition rate and cancer It can be seen that the weight inhibition rate is excellent. Particularly, when the extract of Preparation Example 2 (3: 1 mixed extract) was administered, the tumor size was 1266 mm 3, and the tumor weight was 1.27 g. As a result, the cancer volume inhibition rate was 55% and the cancer weight inhibition rate was 63%. It can be seen that it is the mixing ratio that shows the best hamam effect.
따라서 본 발명에 따른 상황버섯 균사체 분말과 산삼 배양근 혼합 추출물은 항암 효과 평가 실험에서 상황버섯 또는 산삼 단독 추출물보다 우수한 항암효과를 나타냄으로써, 단독 추출물로부터는 예상할 수 없는 상승효과를 나타내는 것을 알 수 있다. 특히 상황버섯 균사체 분말과 산삼 배양근을 3:1 중량비율로 혼합한 경우에는 암 무게 억제율이 약 63%로 측정됨으로써, 약 47%의 암 무게 억제율을 나타내는 상황버섯 및 약 40%의 암 무게 억제율을 나타내는 산삼 단독 추출물에 비해 암 무게 억제율이 약 1.6배 우수한 것을 알 수 있다.
Therefore, the mixed mushroom mycelium powder and wild ginseng cultured root extract according to the present invention showed superior anticancer effect than the situation mushroom or wild ginseng extract alone in the anticancer effect evaluation experiment, and it can be seen that the synergistic effect was unexpected from the single extract. . In particular, when the mycelium mushroom mycelium powder and wild ginseng culture root were mixed at a 3: 1 weight ratio, the cancer weight inhibition rate was measured to be about 63%. It can be seen that cancer weight inhibition rate is about 1.6 times superior to wild ginseng extract alone.
< 실시예 2> 상황버섯 균사체 분말과 산삼 배양근 3:1 혼합 추출물의 투여용량에 따른 항암 효과 평가 < Example 2> Anticancer effect evaluation according to the dosage of the situation mushroom mycelium powder and wild ginseng culture root 3: 1 mixed extract
본 발명에 따른 상황버섯 균사체 분말과 산삼 배양근 3:1 혼합 추출물의 투여용량에 따른 항암 효과를 측정하기 위하여 하기의 실험을 수행하였다.In order to measure the anticancer effect according to the dose of the situation mushroom mycelium powder and wild ginseng culture root 3: 1 mixed extract according to the present invention, the following experiment was performed.
먼저, 실험에 사용한 쥐는 중앙실험동물(주)에서 구입한 일본산 검은 쥐 BDF1 male로서 체중은 20±2 g이었다. 사육온도는 22±2 ℃이었고, 고형사료(삼양사료 Co.)와 물을 충분히 공급하였다. 매 그룹에 사용한 쥐의 수는 10마리이었고, 그 중에서 표준편차가 큰 2마리를 빼고 나머지 8마리의 결과를 데이터로 정리하였다. 추출용 용매는 1급 시약(E.P.)을 사용하였다. 시료는 대한약품주식회사에서 제조한 멸균생리식염수를 사용하였다. 암세포배양에 사용한 RPMI 1640 배지는 WelGENE Inc.에서 제공한 배지를 사용하였고, 트립신-EDTA는 GIBCO사 것을 사용하였다. 세포배양에 필요한 시험관과 배양용 플라스크 그리고 암세포를 얻기 위한 필터는 팔콘사 것을 사용하였다. 암 이식에 사용한 기구들은 120 ℃에서 30분 동안 소독한 기구들을 사용하였으며, 암의 부피는 디지털 캘리퍼(Digital Caliper)를 사용하여 그 부피를 측정하였다. 실험에 사용한 폐암(Lewis Lung Carcinoma, LLC)세포는 한국생명공학연구원에서 분양받아 사용하였다. 폐암세포는 10% FBS를 넣은 RPMI 1640 배지로 37 ℃의 배양기에서 배양하였고, 부착면으로부터 분리할 때는 트립신-EDTA를 사용하였다. 200 ㎖의 배양용 플라스크에 세포가 차면 2마리의 동물에 이식하여 폐암 세포를 키운 후 그것을 사용하여 동물실험을 진행하였다.First, the rats used in the experiment were Japanese black rats BDF 1 male, purchased from Central Experimental Animal Co., Ltd., and weighed 20 ± 2 g. The breeding temperature was 22 ± 2 ℃, and the solid feed (Samyang Feed Co.) and water were sufficiently supplied. The number of rats used in each group was 10, and two of them with large standard deviations were subtracted and the remaining eight were summarized as data. As a solvent for extraction, a primary reagent (EP) was used. As a sample, sterile physiological saline prepared by Korea Pharmaceutical Co., Ltd. was used. RPMI 1640 medium used for cancer cell culture was used as a medium provided by WelGENE Inc., and trypsin-EDTA was used as GIBCO. Falcon was used as a filter for obtaining test tubes, culture flasks, and cancer cells necessary for cell culture. The instruments used for cancer implantation were used sterilized for 30 minutes at 120 ℃, the volume of the cancer was measured using a digital caliper (Digital Caliper). The lung cancer cells (Lewis Lung Carcinoma, LLC) used in the experiment were distributed by the Korea Research Institute of Bioscience and Biotechnology. Lung cancer cells were cultured in an incubator at 37 ℃ in RPMI 1640 medium containing 10% FBS, trypsin-EDTA was used to separate from the adhesion surface. When cells were filled in a 200 ml culture flask, two animals were transplanted to grow lung cancer cells, and then animal experiments were performed using them.
항암동물실험은 약 15×15×15 ㎣ 크기로 자란 종양을 수술하여 필터를 이용하여 암세포를 다른 세포와 분리하였으며, 여러 번 세척하여 얻은 암세포를 2×105 cell/㎖의 농도로 만들어 실험동물의 겨드랑이에 0.1 ㎖씩 주사하여 암을 유발하였다. 암 이식 후 다음날부터 14일간 상기 제조예 2의 추출물을 각각 50, 100 및 200 ㎎/㎏의 용량으로 일본산 검은 쥐에게 매일 경구투여하였다. 비교군으로 비교제조예 1의 추출물을 각각 100 ㎎/㎏, 200 ㎎/㎏의 용량으로, 현재 항암제로 널리 사용되는 탁솔(Taxol)을 20 ㎎/㎏의 용량으로 14일 동안 매일 1회 경구투여 하였으며, 대조군에는 아무런 처리를 하지 않았다. 14일 후, 투여를 중지한 후, 디지털 캘리퍼(Digital Caliper)를 사용하여 결과를 측정하였다. 암의 부피, 암 부피 억제율 및 암 무게 억제율의 계산은 상기 수학식 1 내지 수학식 3에 의해 계산하였다.Anti-cancer animal experiment is about 15 × 15 × 15 ㎣ Cancer cells were isolated from other cells using a filter that had grown to a tumor grown in size, and cancer cells obtained by washing several times were injected at a concentration of 2 × 10 5 cell / ml into the experimental animal's armpits to induce cancer. It was. The extract of Preparation Example 2 was orally administered daily to Japanese black rats at doses of 50, 100 and 200 mg / kg, respectively, for 14 days from the next day after cancer transplantation. In the comparative group, the extract of Comparative Preparation Example 1 was dosed at 100 mg / kg and 200 mg / kg, respectively, and Taxol, which is widely used as an anticancer agent, was orally administered once daily for 14 days at a dose of 20 mg / kg. The control group was not treated. After 14 days, after discontinuation, the results were measured using a digital caliper. The calculation of cancer volume, cancer volume inhibition rate and cancer weight inhibition rate was calculated by the above equations (1) to (3).
그 결과를 하기 표 2 및 도 4 내지 6에 나타내었다. 모든 데이터는 mean±S.D.로 나타냈으며, 분석은 Anova test를 실시하였고, p values는 0.05 이하인 경우 유의성이 있다고 하였다. 보다 상세하게는 본 발명에 따른 제조예 2의 추출물을 투여한 경우에 암 부피 억제율을 도 4에 나타내었고, 암 무게 억제율을 도 5에 나타내었으며, 종양 이미지를 도 6에 나타내었다.The results are shown in Table 2 below and FIGS. 4 to 6. All data were expressed as mean ± SD. The analysis was performed by Anova test, and p values were less than 0.05. In more detail, in the case of administering the extract of Preparation Example 2 according to the present invention, the cancer volume inhibition rate is shown in FIG. 4, the cancer weight inhibition rate is shown in FIG. 5, and the tumor image is shown in FIG. 6.
(㎣)Tumor size
(㎣)
(%)Cancer volume inhibition rate
(%)
(g)Tumor weight
(g)
(%)Cancer weight inhibition rate
(%)
제조예 2
Preparation Example 2
상기 표 2 및 도 4 내지 도 6에 나타낸 바와 같이, 상기 비교제조예 1(100 ㎎/㎏), 비교제조예 1(200 ㎎/㎏) 및 제조예 2의 추출물을 투여한 경우 아무런 처리를 하지 않은 대조군과 비교하여, 모두 종양크기 및 종양무게가 감소하였으며, 암 부피 억제율 및 암 무게 억제율이 증가하는 것을 알 수 있다. 특히, 상기 제조예 2의 추출물을 200 ㎎/㎏의 용량으로 투여한 경우에는 종양크기가 3400 ㎣, 종양 무게가 3.05 g 감소한 결과, 암 부피 억제율이 62%, 암 무게 억제율이 62%로 측정됨으로써 현재 항암제로 널리 사용되는 탁솔보다 우수한 항암 효과를 나타내는 것을 알 수 있다.As shown in Table 2 and Figures 4 to 6, when the extract of Comparative Preparation Example 1 (100 mg / kg), Comparative Preparation Example 1 (200 mg / kg) and Preparation Example 2 was administered no treatment Compared with the control group, the tumor size and tumor weight were all reduced, and the cancer volume inhibition rate and cancer weight inhibition rate were increased. Particularly, when the extract of Preparation Example 2 was administered at a dose of 200 mg / kg, the tumor size was reduced to 3400 mm 3 and tumor weight was 3.05 g. As a result, the cancer volume inhibition rate was 62% and the cancer weight inhibition rate was 62%. It can be seen that it shows an excellent anticancer effect than Taxol which is currently widely used as an anticancer agent.
따라서 본 발명에 따른 상황버섯 균사체 분말과 산삼 배양근 혼합 추출물은 투여용량에 따른 항암 효과 평가 실험에서 투여용량이 증가할수록 암 무게 억제율 및 암 부피 억제율이 증가함으로써 용량의존적인 항암 효과를 나타내며, 특히 상황버섯 균사체 분말과 산삼 배양근 3:1 중량비율 혼합 추출물을 200 ㎎/㎏의 용량으로 투여하는 경우에 탁솔에 비해 암 무게 억제율이 약 1.5배, 암 부피 억제율이 약 1.7배 우수한 것을 알 수 있다.
Therefore, the situation mushroom mycelium powder and wild ginseng culture root mixed extract according to the present invention shows dose-dependent anticancer effect by increasing the cancer weight inhibition rate and cancer volume inhibition rate as the dose is increased in the anticancer effect evaluation experiment according to the dose. When the mycelia powder and wild ginseng culture root 3: 1 weight ratio mixed extract is administered at a dose of 200 mg / kg, it can be seen that cancer weight suppression rate is about 1.5 times and cancer volume inhibition rate is about 1.7 times superior to Taxol.
그러므로 본 발명에 따른 상황버섯 균사체 분말과 산삼 배양근 혼합 추출물은 상황버섯 균사체 분말과 산삼 배양근을 1:1 내지 5:1의 중량비율로 혼합함으로써 상황버섯 또는 산삼 단독 추출물보다 우수한 항암효과를 나타내며, 특히 상황버섯 균사체 분말과 산삼 배양근을 3:1의 중량비율로 혼합하는 경우에 가장 우수한 항암 효과를 나타내는바, 이는 현재 항암제로 널리 사용되는 탁솔의 항암 효과보다도 우수하므로 본 발명에 따른 상황버섯 균사체 분말과 산삼 배양근 혼합 추출물은 암의 예방 또는 개선을 위한 건강기능 식품 조성물로 유용하게 사용될 수 있을 뿐만 아니라, 암의 예방 또는 치료를 위한 약학적 조성물로 유용하게 사용될 수 있다.
Therefore, the mixed mushroom mushroom mycelium powder and wild ginseng cultured root extract according to the present invention show superior anticancer effect by mixing the mushroom mushroom mycelium powder and wild ginseng cultured root at a weight ratio of 1: 1 to 5: 1, especially Situation mushroom mycelium powder and wild ginseng culture root showed the best anti-cancer effect when mixed in a weight ratio of 3: 1, which is superior to the anticancer effect of Taxol which is widely used as an anticancer agent. Wild ginseng culture root mixed extract can be usefully used as a health food composition for the prevention or improvement of cancer, as well as a pharmaceutical composition for the prevention or treatment of cancer.
하기에 본 발명의 암의 예방 또는 개선을 위한 제제예를 예시한다.Examples of preparations for the prevention or improvement of the cancer of the present invention are illustrated below.
제제예Formulation example 1. 건강기능 식품의 제조 1. Preparation of dietary supplements
1-1. 음료의 제조1-1. Manufacturing of beverages
꿀 522 ㎎522 mg of honey
치옥토산아미드 5 ㎎Chioctosanamide 5 mg
니코틴산아미드 10 ㎎Nicotinamide 10 mg
염산리보플라빈나트륨 3 ㎎Riboflavin Sodium Hydrochloride 3 mg
염산피리독신 2 ㎎Pyridoxine hydrochloride 2 mg
이노시톨 30 ㎎Inositol 30 mg
오르트산 50 ㎎Orthoic acid 50 mg
상황버섯 균사체 분말과 산삼 배양근 혼합 추출물 0.48-1.28 ㎎Situation Mushroom Mycelia Powder and Wild Ginseng Cultured Root Extract 0.48-1.28 mg
물 200 ㎖200 ml of water
상기 조성 및 함량으로 하여 통상적인 방법을 사용하여 음료를 제조하였다.
A beverage was prepared using the above-mentioned composition and content by a conventional method.
1-2. 1-2. 츄잉껌의Of chewing gum 제조 Produce
껌베이스 20%
설탕 76.36-76.76%Sugar 76.36-76.76%
상황버섯 균사체 분말과 산삼 배양근 혼합 추출물 0.24-0.64%Situation Mushroom Mycelia Powder and Wild Ginseng Cultured Root Extract 0.24-0.64%
후르츠향 1%1% of fruit flavor
물 2%Water 2%
상기 조성 및 함량으로 하여 통상적인 방법을 사용하여 츄잉껌을 제조하였다.
Chewing gum was prepared using the above-mentioned composition and content by a conventional method.
1-3. 캔디의 제조1-3. Manufacture of candy
설탕 50-60%50-60% sugar
물엿 39.26-49.66%Starch syrup 39.26-49.66%
상황버섯 균사체 분말과 산삼 배양근 혼합 추출물 0.24-0.64%Situation Mushroom Mycelia Powder and Wild Ginseng Cultured Root Extract 0.24-0.64%
오렌지향 0.1%Orange flavor 0.1%
상기 조성 및 함량으로 하여 통상적인 방법을 사용하여 캔디를 제조하였다.
The composition and the content of the candy were prepared using a conventional method.
1-4. 밀가루 식품의 제조1-4. Manufacture of flour food products
본 발명에 따른 상황버섯 균사체 분말과 산삼 배양근 혼합 추출물 0.5 내지 5 중량부를 밀가루 100 중량부에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.
0.5 to 5 parts by weight of the situation mushroom mycelium powder and wild ginseng culture root mixed extract according to the present invention was added to 100 parts by weight of wheat flour, and bread, cake, cookies, crackers and noodles were prepared using the mixture to prepare foods for health promotion. .
1-5. 유제품(1-5. dairy product( dairydairy productsproducts )의 제조Manufacturing
본 발명에 따른 상황버섯 균사체 분말과 산삼 배양근 혼합 추출물 5 내지 10 중량부를 우유 100 중량부에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.
5 to 10 parts by weight of the situation mushroom mycelium powder and wild ginseng culture root mixed extract according to the present invention was added to 100 parts by weight of milk, and various dairy products such as butter and ice cream were prepared using the milk.
1-6. 1-6. 선식의Solar 제조 Produce
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입고 60 메쉬의 분말로 제조하였다.Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted.
검은콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Black soybeans, black sesame seeds, and perilla were also steamed and dried in a known manner, and then roasted to prepare a powder having a particle size of 60 mesh.
상기에서 제조한 곡물류 및 종실류와 본 발명에 따른 상황버섯 균사체 분말과 산삼 배양근 혼합 추출물을 다음과 같은 비율로 배합하여 제조하였다.Cereals and seeds prepared above and the mushroom mushroom mycelium powder and wild ginseng culture root mixed extract according to the present invention were prepared by combining the following ratios.
현미 30%30% brown rice
율무 15%15% rate
보리 20%
들깨 7% Perilla 7%
검정콩 7% Black Bean 7%
검은깨 7%Black Sesame 7%
상황버섯 균사체 분말과 산삼 배양근 혼합 추출물 3%Situation Mushroom Mycelia Powder and Wild Ginseng Cultured Root Extract 3%
영지 0.5%Ganoderma 0.5%
지황 0.5%
Foxglove 0.5%
제제예Formulation example 2: 약학적 제제의 제조 2: Preparation of Pharmaceutical Formulations
2-1. 2-1. 산제의Sanje 제조 Produce
상황버섯 균사체 분말과 산삼 배양근 혼합 추출물 2 g2 g of situation mushroom mycelium powder and wild ginseng cultured root extract
유당 1 g1 g lactose
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.
The above components were mixed and packed in airtight bags to prepare powders.
2-2. 정제의 제조2-2. Manufacture of tablets
상황버섯 균사체 분말과 산삼 배양근 혼합 추출물 100 ㎎Situation Mushroom Mycelia Powder and Wild Ginseng Culture Root Extract 100 mg
옥수수전분 100 ㎎
유당 100 ㎎
스테아린산 마그네슘 2 ㎎2 mg magnesium stearate
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.
After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
2-3. 캡슐제의 제조2-3. Preparation of capsules
상황버섯 균사체 분말과 산삼 배양근 혼합 추출물 100 ㎎Situation Mushroom Mycelia Powder and Wild Ginseng Culture Root Extract 100 mg
옥수수전분 100 ㎎
유당 100 ㎎
스테아린산 마그네슘 2 ㎎2 mg magnesium stearate
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.
After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.
2-4. 주사제의 제조2-4. Injection preparation
상황버섯 균사체 분말과 산삼 배양근 혼합 추출물 100 ㎎Situation Mushroom Mycelia Powder and Wild Ginseng Culture Root Extract 100 mg
만니톨 180 ㎎Mannitol 180 mg
Na2HPO4ㆍ2H2O 26 ㎎Na 2 HPO 4 2H 2 O 26 mg
증류수 2974 ㎎Distilled water 2974 mg
통상적인 주사제의 제조방법에 따라, 상기 성분들을 제시된 함량으로 함유시켜 주사제를 제조하였다.According to a conventional method for preparing an injection, an injection was prepared by containing the above components in the contents shown.
Claims (7)
A pharmaceutical composition for preventing or treating lung cancer, which comprises a mushroom mushroom mycelium powder and a wild ginseng cultured root 1: 1 to 5: 1 weight ratio mixed extract as an active ingredient.
The method of claim 1, wherein the mixed extract is selected from the group consisting of water, C1 to C2 alcohol, ethyl acetate, methylene chloride and chloroform or lung cancer, characterized in that extracted using a mixed solvent thereof Therapeutic pharmaceutical composition.
The pharmaceutical composition for preventing or treating lung cancer according to claim 2, wherein the alcohol is ethanol.
6. The pharmaceutical composition for preventing or treating lung cancer according to claim 5, wherein the ethanol is 40-60% ethanol.
A pharmaceutical composition for preventing or treating lung cancer, comprising a mushroom mushroom mycelium powder and a wild ginseng cultured root 3: 1 weight ratio mixed extract as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110105871A KR101257909B1 (en) | 2011-10-17 | 2011-10-17 | Pharmaceurtical compositions for the prevention or treatment of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110105871A KR101257909B1 (en) | 2011-10-17 | 2011-10-17 | Pharmaceurtical compositions for the prevention or treatment of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020090114697A Division KR101160943B1 (en) | 2009-11-25 | 2009-11-25 | Health functional foods compositions for the prevention and amelioration of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20110119606A KR20110119606A (en) | 2011-11-02 |
| KR101257909B1 true KR101257909B1 (en) | 2013-04-24 |
Family
ID=45391123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020110105871A KR101257909B1 (en) | 2011-10-17 | 2011-10-17 | Pharmaceurtical compositions for the prevention or treatment of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101257909B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101490786B1 (en) * | 2011-12-09 | 2015-02-09 | 포항공과대학교 산학협력단 | Composition comprising water extracts from fomitella fraxinea (fr.) imaz. for treating or preventing obesity |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100607907B1 (en) * | 2004-12-24 | 2006-08-03 | 경희대학교 산학협력단 | Pharmaceutical composition containing the extract of S. mushrooms with liver metastasis suppression and immunomodulatory effect |
-
2011
- 2011-10-17 KR KR1020110105871A patent/KR101257909B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100607907B1 (en) * | 2004-12-24 | 2006-08-03 | 경희대학교 산학협력단 | Pharmaceutical composition containing the extract of S. mushrooms with liver metastasis suppression and immunomodulatory effect |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110119606A (en) | 2011-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101160943B1 (en) | Health functional foods compositions for the prevention and amelioration of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient | |
| KR101184666B1 (en) | Composition for improving physiological activity of positive constitution | |
| KR101062172B1 (en) | Anti-cancer health food containing mushroom fermented ginseng powder | |
| CN110917291A (en) | Composition with function of improving immunity and preparation method and application thereof | |
| KR101045031B1 (en) | Composition for enhancing immune function containing Cucumber fruit extract | |
| US20180296615A1 (en) | Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient | |
| KR101039110B1 (en) | Immunity Enhancement Composition Containing Water Extract of Methanol | |
| US7371416B2 (en) | Method for preparing processed ginseng to obtain increased amount of ginsenoside RG5 | |
| KR20170109703A (en) | A pharmaceutical composition for preventing or treating cancer comprising fractions of herbal mixture extract | |
| KR101033671B1 (en) | Health foods for cancer including situational mushrooms and cordyceps | |
| KR100921909B1 (en) | Health food composition containing butanol fraction of deodeok with hematopoietic stem cell proliferation | |
| KR101018403B1 (en) | Gout prevention, delaying or therapeutic composition containing soybean leaf extract as an active ingredient | |
| KR101257909B1 (en) | Pharmaceurtical compositions for the prevention or treatment of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient | |
| KR20190002775A (en) | Composition for preventing or treating atopic dermatitis comprising Akebia quinata extracts or fractions thereof as an active ingredient | |
| KR102085582B1 (en) | Composition for antitumor or inducing antitumor immune response comprising Erysimum sp. extract as effective component | |
| KR100827350B1 (en) | Hypoglycemic herbal composition | |
| KR101514284B1 (en) | The pharmaceutical composition for prevention or treatment of cancer comprising an extract of Oplopanax elatus | |
| KR101712889B1 (en) | Pharmaceutical composition comprising Zingiber mioga extracts or its fractions for prevention and treatment of neurodegenerative disorders as an active ingredient | |
| KR101033003B1 (en) | Composition for enhancing immune function containing low fruit extract | |
| KR20190041350A (en) | Composition comprising extract of Panax ginseng and Liriope platyphylla for preventing or treating learning, cognition or memory disabilities | |
| KR101266998B1 (en) | Composition for reducing weight, preventing and treating obesity by containing the extract of Crepidiastrum denticulatum | |
| KR100593533B1 (en) | Immune activity enhancing composition containing Felinus vaginal mycelium extract | |
| KR20240029006A (en) | Food Composition For Improving Skin Elasticity Or Moisture | |
| KR20210044532A (en) | Composition for Detoxifying Dioxin Toxicity Comprising Water-soluble Non-saponin Components Derived from Ginseng | |
| KR20210047168A (en) | Functional tea containing extracts of chaga, edible mushrooms and ganoderma lucidum and probiotics as active ingredients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20111017 Patent event code: PA01071R01D |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20111208 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20120720 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20130121 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20130418 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20130419 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20160324 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160324 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20170323 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170323 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20180410 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180410 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20190321 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190321 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20200219 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200219 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210217 Start annual number: 9 End annual number: 9 |
|
| PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20230129 |